Methods: We report the first case of documented hemolytic anemia resulting from exposure to C/A.
Results: A 67 year old lady was admitted to University Medical Center of Southern Nevada from a skilled nursing facility for management of a left upper quadrant abdominal wall abscess at the site of a prior chest tube. After undergoing surgical debridement, cultures revealed a carbapenemase producing K. pneumoniae. She was initiated on C/A, becoming tachycardic and hypotensive within 72 hours. She was noted to have an acute drop in hemoglobin from 9.4g/dL to 6.8g/dL, along with an undetectable haptoglobin; elevated LDH and retic count. A direct Coombs test was positive. Review of medications pointed to C/A as the possible offending agent. She was treated with blood transfusions and C/A was discontinued. Within 3 days, the patient demonstrated improvement of her clinical symptoms.
Conclusion: In phase III trials, 1.9% of patients on C/A had a documented positive conversion of a previously negative direct Coombs test; however none of the patients developed clinical evidence of hemolytic anemia. Ceftazidime, the base compound of this combination, has been available for use in the US since 1985 with 7 documented cases of acute hemolytic anemia. Based on these case reports it is reasonable to assume that the combination of ceftazidime and avibactam could also result in this life threatening adverse effect. As such, if a patient develops symptoms of hemolytic anemia, C/A should be included in the list of causative agents and discontinued pending further workup and patient stabilization
K. D. Leuthner,
A. Yousif, None
S. Asad, None